{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:31:07Z","timestamp":1756992667248},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1993,4,1]],"date-time":"1993-04-01T00:00:00Z","timestamp":733622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drug Ther"],"published-print":{"date-parts":[[1993,4]]},"DOI":"10.1007\/bf00878518","type":"journal-article","created":{"date-parts":[[2004,12,28]],"date-time":"2004-12-28T00:31:27Z","timestamp":1104193887000},"page":"273-282","source":"Crossref","is-referenced-by-count":28,"title":["The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention"],"prefix":"10.1007","volume":"7","author":[{"given":"Michele","family":"Texter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Dinsmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C. G.","family":"Uprichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0140-6736(90)91656-U","volume":"336","author":"D Ornish","year":"1990","unstructured":"Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease?Lancet 1990;336:129?133.","journal-title":"Lancet"},{"key":"CR2","first-page":"242","volume":"1","author":"DH Blankenhorn","year":"1981","unstructured":"Blankenhorn DH, Brooks SH. Angiographic trials of lipid-lowering therapy.Arteriosclerosis 1981;1:242?249","journal-title":"Arteriosclerosis"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0197-2456(87)90156-5","volume":"8","author":"DH Blankenhorn","year":"1987","unstructured":"Blankenhorn DH, Johnson RL, Nessim SA, et al. and the CLAS Investigators and Staff. The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, methods, and baseline results.Controlled Clin Trial 1987;8:354?387.","journal-title":"Controlled Clin Trial"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","volume":"323","author":"G Brown","year":"1990","unstructured":"Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.N Engl J Med 1990;323:1289?1298.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"CR5","first-page":"I1","volume":"49","author":"H Buchwald","year":"1974","unstructured":"Buchwald H, Moore RB, Varco RL. Surgical treatment of hyperlipidemia.Circulation 1974;49(Suppl 1):I1-I37.","journal-title":"Circulation"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","volume":"323","author":"H Buchwald","year":"1990","unstructured":"Buchwald H, Varco RL, Matts JP, et al. and the POSCH Grou. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia.N Engl J Med 1990;323:946?955.","journal-title":"N Engl J Med"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0140-6736(90)91121-P","volume":"335","author":"PR Lichtlen","year":"1990","unstructured":"Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine.Lancet 1990;335:1109?1113.","journal-title":"Lancet"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1161\/01.CIR.82.6.1940","volume":"82","author":"D Waters","year":"1990","unstructured":"Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker upon progression of coronary atherosclerosis.Circulation 1990;82:1940?1954.","journal-title":"Circulation"},{"key":"CR9","first-page":"529","volume":"48","author":"G Foris","year":"1983","unstructured":"Foris G, Dezso B, Medgyesi GA, Fust G. Effect of angiotensin II on macrophage functions.Immunology 1983;48:529?535.","journal-title":"Immunology"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/01.HYP.15.3.327","volume":"15","author":"A Chobanian","year":"1990","unstructured":"Chobanian A, Haudenschild C, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.Hypertension 1990;15:327?331.","journal-title":"Hypertension"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/01.HYP.15.6.666","volume":"15","author":"AV Chobanian","year":"1989","unstructured":"Chobanian AV. 1989 Corcoran Lecture: Adaptive and maladaptive response of the arterial wall to hypertension.Hypertension 1990;15:666?674.","journal-title":"Hypertension"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1111\/j.1365-2125.1989.tb03585.x","volume":"28","author":"PM Vanhoutte","year":"1989","unstructured":"Vanhoutte PM, Auch-Schwelk W, Biondi ML, et al. Why are converting enzyme inhibitors vasodilators?Br J Clin Pharmacol 1989;28:95S-104S.","journal-title":"Br J Clin Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.2526370","volume":"245","author":"JS Powell","year":"1989","unstructured":"Powell JS, Clozel J-P, Muller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.Science 1989;245:186?188.","journal-title":"Science"},{"issue":"Suppl 5","key":"CR14","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00005344-199000005-00010","volume":"15","author":"G Aberg","year":"1990","unstructured":"Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys.J Cardiovasc Pharmacol 1990;15(Suppl 5):S65-S72.","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/01.CIR.86.1.100","volume":"86","author":"The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group","year":"1992","unstructured":"The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?Circulation 1992;86:100?110.","journal-title":"Circulation"},{"key":"CR16","unstructured":"The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Presented at XVth Congress of the European College of Cardiology, September, 1991; Amsterdam, The Netherlands."},{"key":"CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991;325:293?302.","journal-title":"N Engl J Med"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/0140-6736(92)92889-N","volume":"340","author":"S Yusuf","year":"1992","unstructured":"Yusuf S, Pepine C, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low election fraction.Lancet 1992;340:1172?1178.","journal-title":"Lancet"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"M Pfeffer","year":"1992","unstructured":"Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med 1992;327:669?677","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"CR20","first-page":"S1","volume":"14","author":"VJ Dazu","year":"1989","unstructured":"Dazu VJ. Short- and long-term determinants of cardiovascular function and therapy: contributions of circulating and tissue renin-angiotensin systems.J Cardiovasc Pharmacol 1989;14(Suppl 4):S1-S5.","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1476-5381.1990.tb15862.x","volume":"100","author":"B Fabris","year":"1990","unstructured":"Fabris B, Yamada H, Cubela R, et al. Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.Br J Pharmacol 1990;100:652?655.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 3","key":"CR22","first-page":"S17","volume":"6","author":"CI Johnston","year":"1988","unstructured":"Johnston CI, Mendelsohn FAO, Cubela RB, et al. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration in ACE inhibitors.J Hypertens 1988;6(Suppl 3):S17-S22.","journal-title":"J Hypertens"},{"key":"CR23","first-page":"273","volume-title":"Quantitation of coronary dimensions using digital image processing. Proceedings of SPIE?The International Society for Optical Engineering","author":"El Alderman","year":"1981","unstructured":"Alderman El, Berte LE, Harrison DC, Sanders W. Quantitation of coronary dimensions using digital image processing. Proceedings of SPIE?The International Society for Optical Engineering. Palo Alto, CA: Stanford University, 1981, pp 273?278."},{"key":"CR24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ccd.1810240211","volume":"24","author":"WH Leung","year":"1991","unstructured":"Leung WH, Sanders W, Alderman EL. A coronary artery quantitation and data management system for paired cineangiograms.Cathet Cardiovasc Diagn 1991;24:121?134.","journal-title":"Cathet Cardiovasc Diagn"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ccd.1810210305","volume":"21","author":"WH Leung","year":"1990","unstructured":"Leung WH, Demopulos PA, Alderman El, Sanders W, Stadius ML. Evaluation of catheters and metallic catheter markers as calibration standard for measurement of coronary dimension.Cathet Cardiovasc Diagn 1990;21:148?153.","journal-title":"Cathet Cardiovasc Diagn"},{"issue":"6","key":"CR26","first-page":"I1","volume":"63","author":"National Heart, Lung, and Blood Institute Coronary Artery Surgery Study","year":"1981","unstructured":"National Heart, Lung, and Blood Institute Coronary Artery Surgery Study. A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography.Circulation 1981;63(6, Part 2):I1-I81.","journal-title":"Circulation"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/biomet\/70.3.659","volume":"70","author":"KKG Lan","year":"1983","unstructured":"Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials.Biometrika 1983;70:659?663.","journal-title":"Biometrika"},{"issue":"Suppl IV","key":"CR28","first-page":"IV9","volume":"81","author":"DP Faxon","year":"1990","unstructured":"Faxon DP, Ruocco N, Jacobs AK. Long term outcome of patients after percutaneous transluminal coronary angioplasty.Circulation 1990;81(Suppl IV):IV9-IV13.","journal-title":"Circulation"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/01.CIR.83.6.1905","volume":"83","author":"S Ellis","year":"1991","unstructured":"Ellis S, Cowley M, DiSciascio G, et al. Determinants of 2-year outcome after coronary angioplasty in patients with multivessel disease on the basis of comprehensive preprocedural evaluation. Implication for patient selection.Circulation 1991;83:1905?1914.","journal-title":"Circulation"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1056\/NEJM198704303161805","volume":"316","author":"AR Gruentzig","year":"1987","unstructured":"Gruentzig AR, King SB, Schlumph M, Siengenthaler W. Long-term follow up after percutaneous transluminal coronary angioplasty. The early Zurich experience.N Engl J Med 1987;316:1127?1132.","journal-title":"N Engl J Med"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/01.CIR.80.3.421","volume":"80","author":"K Detre","year":"1989","unstructured":"Detre K, Holubkov R, Kelsey S, et al. and coinvestigators of the National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry.Circulation 1989;80:421?428.","journal-title":"Circulation"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/01.CIR.77.4.820","volume":"77","author":"JD Talley","year":"1988","unstructured":"Talley JD, Hurst JW, King SB, et al. Clinical outcome 5 years after attempted percutaneous transluminal coronary angioplasty in 427 patients.Circulation 1988;77:820?829.","journal-title":"Circulation"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/01.CIR.84.2.572","volume":"84","author":"WS Weintraub","year":"1991","unstructured":"Weintraub WS, Ghazzal ZMB, Cohen CL, et al. Clinical implications of late proven patency after successful coronary angioplasty.Circulation 1991;84:572?582.","journal-title":"Circulation"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJM198503283121301","volume":"312","author":"AC Arntzenius","year":"1985","unstructured":"Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.N Engl J Med 1985;312:805?811.","journal-title":"N Engl J Med"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","volume":"257","author":"DH Blankenhorn","year":"1987","unstructured":"Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.JAMA 1987;257:3233?3240.","journal-title":"JAMA"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/01.CIR.81.2.470","volume":"81","author":"DH Blankenhorn","year":"1990","unstructured":"Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in naive human arteries and aortocoronary bypass grafts.Circulation 1990;81:470?476.","journal-title":"Circulation"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0002-8703(75)90504-9","volume":"89","author":"K Cohn","year":"1975","unstructured":"Cohn K, Sakai FJ, Langston MF. Effect of clofibrate on progression of coronary disease. A prospective angiographic study in man.Am Heart J 1975;89:591?598.","journal-title":"Am Heart J"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0002-9149(83)90397-1","volume":"52","author":"MH Frick","year":"1983","unstructured":"Frick MH, Valle M, Harjola P-T. Progression of coronary artery disease in randomized medical and surgical patients over a 5-year angiographic follow-up.Am J Cardiol 1983;52:681?685.","journal-title":"Am J Cardiol"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/01.CIR.69.2.325","volume":"69","author":"RI Levy","year":"1984","unstructured":"Levy RI, Brensike JF, Epstein SE, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study.Circulation 1984;69:325?337.","journal-title":"Circulation"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0197-2456(87)90046-8","volume":"8","author":"D Waters","year":"1987","unstructured":"Waters D, Freedman D, Lesperance J, et al. Design features of a controlled clinical trial to assess the effect of a calcium entry blocker upon the progression of coronary artery disease.Controlled Clin Trials 1987;8:216?242.","journal-title":"Controlled Clin Trials"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/0735-1097(90)90317-I","volume":"16","author":"KN Garratt","year":"1990","unstructured":"Garratt KN, Holmes DR, Bell MR, et al. Restenosis after directional coronary atherectomy: differences between primary atheromatous and restenosis lesions and influence of subintimal tissue resection.J Am Coll Cardiol 1990;16:1665?1675.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00878518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00878518\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00878518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T12:57:37Z","timestamp":1556542657000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00878518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1993,4]]}},"alternative-id":["BF00878518"],"URL":"https:\/\/doi.org\/10.1007\/bf00878518","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,4]]}}}